Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis

Brian H. Horwich1, Tom Z. Liang2, Jennifer L. Dodge3,4, Shefali Chopra2, Jeffrey A. Kahn3,5* and Takeshi Saito2,3,6,7*

1Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, 2Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, 3Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, 4Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, 5USC Transplant Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, 6Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, 7USC Research Center for Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States

Autoimmune hepatitis (AIH), post-transplant recurrent AIH (rAIH), and plasma cell-rich rejection (PCR) are clinical diagnoses with the shared histopathologic hallmark of plasma cell hepatitis (PCH). As these histologically and serologically indistinguishable diagnoses are differentiated by clinical context, it remains uncertain whether they represent distinct immunologic phenomena. Improved understanding of immunoglobulin subclass 4-producing plasma cells (IgG4-PC) has brought attention to IgG4 as an immunophenotypic biomarker. To date, degree and clinical significance of IgG4-PC infiltration in PCH remain elusive. This retrospective, single-center study assessed IgG4-PC infiltration in AIH, rAIH, and PCR via standardized immunohistochemistry analysis. Identified cases from 2005 to 2020 (n = 47) included AIH (treatment-naïve AIH (tnAIH); n = 15 and AIH-flare on treatment (fAIH); n = 10), rAIH (n = 8), and PCR (n = 14) were analyzed and correlated with clinical characteristics. IgG4-Positivity (# IgG4-PC/# pan-IgG-expressing cells) distribution was heterogenous and overlapping [tnAIH: 0.060 (IQR 0.040–0.079), fAIH: 0.000 (0.000–0.033), rAIH: 0.000 (0.000–0.035), PCR: 0.228 (0.039–0.558)]. IgG4-Positivity was inversely correlated with corticosteroid use (p < 0.001). IgG4-Positivity ≥0.500 was associated with rapid AST improvement (p = 0.03). The variable IgG4-Positivity of AIH, rAIH and PCR suggests diverse and overlapping immunopathologic mechanisms and that current diagnostic schemes inadequately capture PCH immunopathology. We propose incorporation of IgG4-Positivity to refine current PCH classification and treatment strategies.

Keywords: plasma cell hepatitis, alloimmunity, autoimmunity, IgG4, autoimmune hepatitis

INTRODUCTION

Plasma cell hepatitis (PCH) is a pathohistological finding characterized by lymphoplasmacytic portal and lobular inflammation with prominent plasma cells and often with the presence of interface hepatitis, perivenulitis and centrilobular necrosis (1–4). While the term “PCH” was originally used to describe autoimmune hepatitis (AIH), its use has extended to other plasma cell (PC)-rich necroinflammatory disorders including recurrent AIH (rAIH) and PC-rich rejection (PCR) in
liver allograft (2, 5–7). Accordingly, the Banff Working Group defines that AIH represents PCH of the native liver, while rAIH and PCR are clinical entities of PCH occurring in the post-LT setting (8–12).

PCH often results in the development of hepatic fibrosis if not promptly and adequately treated with potent immunosuppressants (IS) such as corticosteroids (CS), antimetabolites, and calcineurin inhibitors (13–16). Moreover, IS often fail to sufficiently control hepatic necroinflammation, which eventually leads to liver failure (7, 14, 17, 18). Furthermore, the long-term administration of IS is associated with significant morbidity, including the development of opportunistic infections and neoplasms (19).

Since histopathological and serological assessment do not distinguish between AIH, rAIH, and PCR, their diagnosis is entirely reliant on clinical context, which is coupled with challenges, perhaps ambiguity (8, 12, 20–23). This is especially relevant in differentiating between rAIH and PCR. By convention, PCR refers to PCH in individuals who underwent transplantation for diseases other than AIH (8). Conversely, rAIH refers to PCH occurring in patients transplanted for AIH. Thus, based upon current convention, differentiating between rAIH and PCR may not be plausible in circumstances where pre-LT diagnosis was uncertain (e.g., acute liver failure of unknown etiology or cryptogenic cirrhosis). Furthermore, current PCH classification scheme excludes individuals transplanted for AIH from receiving a diagnosis of PCR. Thus, it remains elusive if rAIH and PCR represent distinctive or overlapping clinical entities. Similarly, there has not been evidence demonstrating that the onset of rAIH is mediated through the recurrence of immunopathology underlying AIH in the native liver, making the nomenclature of rAIH potentially deceiving. Ultimately, the fundamental issue regarding the current classification of PCH is the substantial degree of uncertainty as to whether each disease—as currently classified—represents a unique immunologic phenomenon.

PC, the terminally differentiated B cells, play a major role in the regulation of humoral immunity through the production of immunoglobulin (Ig). PC exhibit highly diverse immunomodulatory effects depending on the classes and subclasses of Ig production such as IgG, A, and M as well as IgG1, 2, 3, and 4, respectively (24). Hence, the Ig classes and subclasses expressed in the infiltrating PC would associate with, at least in part, the immunopathological presentations of PC-mediated disorders (24, 25). In particular, inflammatory disorders with a pronounced infiltration of IgG4-PC have been known to manifest marked tissue fibrosis and favorable response to IS (26). Therefore, chronic inflammatory disorders with IgG4-PC infiltration have emerged as a unique clinical entity, namely IgG4-related diseases (IgG4-RD) (27). The pancreas was the first organ in which IgG4-RD was recognized, namely autoimmune pancreatitis; thereafter this disease entity has been known to affect multiple organs, including the liver parenchyma (27, 28).

Prior studies have demonstrated the infiltration of IgG4-PC in the liver tissue of PCR and native-liver AIH, with a PCR subtype...
demonstrating significant enrichment (28, 29). Consequently, the Banff Working Group recommends use of IgG4 immunostaining in the evaluation of post-LT PCH (12). However, this recommendation lacks a specific threshold for IgG4-PC positivity and does not provide guidance with respect to its clinical relevance. One potential reason for this is that there has not been a comprehensive study that cross-sectionally compares the degree of IgG4-PC infiltration between PCH types with a standardized quantification method, significantly limiting its practical use. In particular, the degree of IgG4-PC infiltration in rAIH has not previously been studied. Thus, it remains elusive whether assessment of IgG4 immunostaining may be of diagnostic and therapeutic relevance in the post-LT setting—particularly in differentiating between rAIH and PCR. The primary aim of this study is to characterize PCH diseases by objectively determining the IgG4-PC positivity and evaluate for associations with clinical presentations and outcomes.

MATERIALS AND METHODS

Study Subject Identification
All study procedures were approved by the University of Southern California Institutional Review Board (HS-19-00258). The study subjects were identified with the Department of Pathology Database by querying for reports containing “AIH,” “PCR,” or “PCH” from 2005 to 2020. The medical record and histopathological finding of all subjects identified through the database were confirmed to meet the diagnostic criteria of AIH (International Autoimmune Hepatitis Group) or PCH (Banff consensus) (12, 30, 31). Individuals with infectious and neoplastic etiologies as the cause of PC infiltration were excluded. All cases enrolled into this study were classified as the following: treatment-naïve AIH (tnAIH), AIH flare while on IS (fAIH), rAIH, and PCR. A diagnosis of tnAIH was defined as meeting probable or definite diagnostic criteria for AIH with no known IS use with activity against AIH prior to biopsy. A diagnosis of fAIH was defined as having a pre-existing diagnosis of AIH on IS with histopathology demonstrating features consistent with recurrence of active AIH disease. A diagnosis of rAIH was defined as allograft histopathology demonstrating features consistent with active AIH disease for which the pre-transplant diagnosis was AIH. A diagnosis of PCR was defined as clinical history and histopathology consistent with criteria outlined by the Banff Working Group (12). No specimen from executed prisoners were used.

Clinical Data Collection
The medical records of identified subjects were reviewed to extract relevant demographic and clinical information.

Specimen Processing and Histopathologic Review
The Formalin-Fixed Paraffin-Embedded (FFPE) liver needle core biopsy specimens of all enrolled cases (n = 47) were retrieved. The hematoxylin-eosin (H&E)-stained pathology slides were first reviewed for adequacy of the tissue as determined by 8 or greater portal tracts and at least 1.5 cm in length. All retrieved samples were deemed adequate by these criteria. For individuals with multiple biopsies with the same diagnosis, the initial biopsy specimen available was used. Cases were evaluated for the following histological characteristics: portal inflammation, interface lobular necro-inflammatory activity, perivenular inflammation and the presence of bridging necrosis. Both activity and fibrosis were assessed on the Metavir histological activity and fibrosis score. Any additional pathological findings were also recorded. The tissue specimens were serially sectioned and applied for immunohistochemical stains using anti-human pan-IgG (RWP49 clone: Leica Biosystems) at 1:1,000 dilution and anti-human IgG4 (MRQ-44 from Cell Marque) at 1:500 dilution. All staining was performed using Bond III Leica Autostainer system at the Human Pathology Core. The representative portal tract of each subject identified by an expert pathologist was used to determine the IgG4-Positivity, which was calculated by the number of IgG4 staining positive PC normalized by the number of pan-IgG staining positive PC in the corresponding portal tract of the serially sectioned slides. Counting was done manually on ×400 of both the IgG and IgG4 cells in that portal tract.

Statistical Analysis
Demographic, laboratory, and histopathologic characteristics were summarized as medians with interquartile ranges (IQR) or frequencies with proportions for the overall cohort and stratified by PCH subtype. Characteristics were compared within the respective non-transplant (tnAIH versus fAIH) and transplant (rAIH versus PCR) groups using Wilcoxon-rank sum or frequencies with proportions for the overall cohort and stratified by PCH subtype. Characteristics were compared by PCH subtype. Measures of IgG4 were characterized as the presence or absence of IgG4-PC and the proportion of IgG4-PC of all IgG-producing cells, which were compared by PCH subtype. The proportion of IgG4-PC was plotted by PCH subtype and separately categorized in tertiles to accommodate the skewed distribution. Laboratory parameters and therapeutic outcomes were evaluated for their association with increasing tertile of IgG4-Positivity using non-parametric trend tests (Stata nptrend) and markedly high IgG4-Positivity in the post-LT groups (≥0.500 vs. <0.500) using Kruskal-Wallis tests (Stata).

Differences were considered statistically significant at p < 0.05. Statistical analysis was conducted using SAS 9.4 (SAS Institute Inc., Cary, NC, United States) and Stata 14.0 (StataCorp, College Station, TX, United States).

RESULTS

Demographics and Clinical Data
The demographics and clinical characteristics of the study subjects are summarized (Table 1). There was no subject crossover between groups. Median age was lowest for rAIH at 35 years compared to 50 or more years for the other PCH subtypes. All groups demonstrated a female predominance (tnAIH 73%, fAIH 60%, rAIH 87%, PCR 79%). Median BMI ranged from 24.3 to 29.5 (tnAIH 26.8, fAIH 24.3, rAIH 28.8, PCR 29.5), with 38% individuals having BMI>30 at time of biopsy. A family history of autoimmune disorders was more
prevalent in the AIH groups (tnAIH 27%, fAIH 20%, rAIH 25%) when compared to PCR (0%). The most common etiologies of pre-transplant liver disease for the PCR group were non-alcoholic steatohepatitis (29%) and acute liver failure of indeterminate etiology (21%).

Calcineurin inhibitor (CNI) and corticosteroids (CS) were the most common IS at biopsy (47% and 45% of all subjects, respectively) (Table 1). Apart from one subject on a longstanding stable regimen of etanercept for rheumatoid arthritis, all other subjects in the tnAIH had received no IS prior to biopsy. In the fAIH group, most subjects were on a CS-based regimen (70%) ± azathioprine (29%) or CNI (14%). IS use in the rAIH group were varied, with CNI (87%) or mammalian target of rapamycin (mTOR) inhibitor (12%) base with the addition of CS (87%), mycophenolate mofetil (MMF) (37%), and/or azathioprine (12%). Among PCR, the IS at biopsy were most commonly CNI-based (93%) with MMF (71%) and/or CS (50%). All episodes of PCR were managed with addition or increase of CS ± uptitration of CNI.

### Table 1 | Characteristics of individuals with plasma cell hepatitis.

| Parameter | All subjects | Non-transplant | Transplant |
|-----------|--------------|----------------|------------|
| **N** | 47 | 15 | 10 | 8 |
| **Age (years), median** | 51 | 52 | 50 | 35 | 52 | 0.22 |
| **Female, n (%)** | 35 (74) | 11 (73) | 6 (60) | 67 (87) | 11 (79) | 1.00* |
| **BMI (kg/m²), median** | 29.1 | 26.8 | 24.3 | 28.8 | 29.5 | 0.86 |
| **Drug use, n (%)** | 3 (6) | 1 (7) | 0 (0) | 1 (12) | 1 (7) | 1.00* |
| **Family history of autoimmune diseases, n (%)** | 8 (17) | 4 (27) | 2 (20) | 2 (25) | 0 (0) | 0.12* |

Liver disease prior to the liver transplantation, n (%)  
- Acute liver failure: 0 (0)  2 (21)  0 (0)  1.00 a  0 (0)  1.00 a  0.12 a
- Alcohol: 0 (0)  2 (21)  0 (0)  1.00 a  0 (0)  1.00 a  0.12 a
- Autoimmune hepatitis: 8 (100)  0 (0)  0 (0)  0.12 a  0 (0)  0 (0)  0.12 a
- Cryptogenic: 0 (0)  2 (21)  0 (0)  1.00 a  0 (0)  1.00 a  0.12 a
- HBV: 0 (0)  0 (0)  0 (0)  1.00 a  0 (0)  1.00 a  0.12 a
- HCV: 0 (0)  0 (0)  0 (0)  1.00 a  0 (0)  1.00 a  0.12 a
- NASH/NAFLD: 0 (0)  0 (0)  0 (0)  1.00 a  0 (0)  1.00 a  0.12 a
- Other: 0 (0)  2 (21)  0 (0)  1.00 a  0 (0)  1.00 a  0.12 a

### Immunosuppressants, n (%)  
- **CS**: 21 (45)  7 (70)  2 (25)  4 (29)  0.17 a
- **CNI**: 22 (47)  2 (20)  7 (87)  13 (93)  1.00 a
- **AZA**: 3 (7)  0 (0)  1 (12)  0 (0)  0.36 a
- **MMF**: 13 (28)  0 (0)  3 (37)  10 (71)  0.19 a
- **MTOR**: 1 (2)  0 (0)  1 (12)  0 (0)  0.36 a

### Laboratory Data  
- **Platelet count (K/cumm), median**: 181  202  195  143  152  0.86
- **ALP (U/L), median**: 216  155  167  204  224  0.68
- **ALT (U/L), median**: 300  349  200  56  181  0.09
- **AST (U/L), median**: 306  366  147  76  155  0.19
- **TB (mg/dl), median**: 5.0  5.3  1.4  0.03  1.3  1.1  0.45
- **Albumin (g/dl), median**: 3.3  3.1  3.5  3.6  3.5  0.81
- **IgG, Total (mg/dl), median**: 7.1  7.1  7.3  7.1  7.0  0.92
- **IgA (mg/dl), median**: 2.1  1.8  2.5  2.1  2.7  0.88
- **IgM (mg/dl), median**: 37.7  37.7  345  504  298  0.18
- **ANA titer (≥1:80), n (%)**: 26 (20)  13 (87)  5 (62)  0.21  1 (9)  0.12 a
- **ASMA (≥20 U), n (%)**: 14 (47)  13 (87)  5 (62)  2 (40)  6 (50)  0.81

**Bolded values represent statistically significant difference (p < 0.05).**

---

*Hepatitis B virus; HCV, Hepatitis C virus; NASH/NAFLD, Nonalcoholic steatohepatitis/nonalcoholic fatty liver disease; CS, corticosteroids; CNIs, calcineurin inhibitors; AZA, azathioprine; MMF, mycophenolate mofetil; mTOR, mammalian target of rapamycin inhibitor; TB, total bilirubin; ANA, Anti-nuclear antibody; ASMA, Anti-smooth muscle antibody.

aFisher's exact test.

bAll subjects were HBsAg negative. One subject in tnAIH was AMA positive. Two subjects (one PCR, one tnAIH) were HCV Ab positive, HCV RNA in these subjects were negative.

cPercent with data available.

dNo data available.
Histopathological Comparison of Plasma Cell Hepatitis Subtypes

The H&E stained and trichome stained section of liver needle biopsy specimen were reviewed by a liver pathologist for the aforementioned features (Table 2). In the non-transplant groups, tnAIH demonstrated greater median total lymphocyte count (p = 0.01), median total plasma cell count (p = 0.003), severity of lobular inflammation (p = 0.046), and presence of interface hepatitis (p < 0.001) compared to fAIH. In the post-transplant groups, PCR demonstrated higher median number of plasma cells (p < 0.001) and proportion of plasma cells relative to total lymphocyte count (p < 0.001) compared to rAIH. However, the overall histologic similarities among PCH subtypes did not allow for definitive differentiation based on the histopathological assessment with H&E staining.

Comparison of IgG4-PC Infiltration

To investigate whether each PCH disease reflects distinctive or overlapping immuno-pathologies, we further examined the specimen by immunophenotyping of infiltrating PC via immunohistochemical analysis of IgG4 expression. IgG4-PC was identified in 30 cases (64%), while the remaining 17 cases did not exhibit the presence of IgG4-PC (Table 3). IgG4-PC was not seen in the lobular inflammatory component of any cases.

| Parameter | All subjects | Non-transplant | Post-transplant |
|-----------|--------------|----------------|----------------|
| Parameter | All subjects | Non-transplant | Post-transplant |
| Lymphocytic Infiltration (cells/tract), median | | | |
| Total lymphocytes | 137.0 | 167 | 105 | 0.01 |
| Total plasma cells | 37.1 | 50 | 20 | 0.003 |
| % Plasma cells | 30.0 | 30 | 20 | 0.26 |
| Fibrosis | | | |
| Mild/minimal | 24 (51) | 6 (40) | 3 (30) | 1.00 |
| Moderate/severe | 23 (49) | 9 (60) | 7 (70) | 1.00 |
| Portal Inflammation, n (%) | | | |
| Mild/minimal | 9 (19) | 1 (7) | 1 (10) | 1.00 |
| Moderate/severe | 38 (81) | 14 (83) | 9 (90) | 1.00 |
| Lobular inflammation, n (%) | | | |
| Mild/minimal | 30 (64) | 4 (27) | 7 (70) | 0.046 |
| Moderate/severe | 17 (36) | 11 (73) | 3 (30) | 0.27 |
| Perivenular inflammation, n (%) | | | |
| Mild/minimal | 30 (64) | 7 (47) | 8 (80) | 0.14 |
| Moderate/severe | 17 (36) | 8 (53) | 2 (20) | 0.19 |
| Bridging necrosis, present, n (%) | | | |
| Mild/minimal | 11 (23) | 8 (53) | 2 (20) | 0.21 |
| Interface hepatitis, present, n (%) | | | |
| Mild/minimal | 38 (81) | 15 (100) | 7 (70) | <0.001 |
| Perivenular necrosis, present, n (%) | | | |
| Mild/minimal | 17 (36) | 8 (53) | 2 (20) | 0.18 |

*Fisher’s exact.
Bolded values represent statistically significant difference (p < 0.05).

| Parameter | All subjects | Non-transplant | Transplant |
|-----------|--------------|----------------|------------|
| Prevalence of IgG4-PC, n (%) | | | |
| IgG4-PC Present | 30 (64) | 13 (87) | 4 (40) |
| IgG4-PC Absent | 17 (36) | 2 (13) | 6 (60) |
| IgG4-Positivity | | | |
| IgG4-PC, median | 0.040 | 0.060 | 0.000 |
| IgG4-PC/IgG-PC, IQR | 0.000–0.0177 | 0.000–0.0177 | 0.000–0.000 |
| IgG4-Positivity Tertile | 1 | 2 | 3 |
| 1 | 17 (36) | 2 (13) | 6 (60) |
| 2 | 15 (32) | 9 (60) | 3 (30) |
| 3 | 15 (32) | 4 (27) | 1 (10) |

IgG4-PC: immunoglobulin G subclass 4-positive plasma cells.
IgG-PC: immunoglobulin G-positive plasma cells.
*Fisher’s exact test.
Bolded values represent statistically significant difference (p < 0.05).
Prevalence of IgG4-PC was highest for tnAIH (87%) followed by PCR (79%), fAIH (40%), and rAIH (25%). The IgG4-Positivity, defined as the number of IgG4-PC over the total number of IgG-expressing PC in the corresponding portal tract, was highly divergent among the PCH types (Figures 1, 2). The diagnosis of PCR demonstrated the highest median IgG4-Positivity (0.228, IQR 0.039–0.558), followed by tnAIH (0.060, IQR 0.040–0.079), rAIH (0.000, IQR 0.000–0.035), and fAIH (0.000, IQR 0.000–0.033).

In the non-transplant groups, tnAIH demonstrated a higher median IgG4-Positivity than fAIH (p = 0.03). In the transplant groups, PCR demonstrated a higher median IgG4-Positivity than rAIH (p = 0.03) (Table 3). Five subjects with IgG4-Positivity ≥0.500 were all in the PCR group (Figure 2). No rAIH subjects demonstrated this degree of IgG4-Positivity. These observations raise the possibility that PCH is comprised of heterogenous immunophenotypes as the IgG4-Positivty is highly variable among and within PCH subtypes.
### TABLE 4 | Clinical and histopathologic characteristics stratified by IgG4-positivity.

| Parameters                                      | IgG4-positivity | Tertile | 1          | 2          | 3          | p-value |
|------------------------------------------------|-----------------|---------|------------|------------|------------|---------|
| Age (years), median                            |                 |         | 41         | 50         | 57         | 0.11    |
| BMI (kg/m²), mean                              |                 |         | 27.41      | 31.98      | 27.62      | 0.64    |
| Female, n (%)                                   |                 |         | 13 (76)    | 12 (80)    | 10 (67)    | 0.54    |
| Family history of autoimmune diseases, n (%)   |                 |         | 2 (12)     | 2 (13)     | 4 (27)     | 0.27    |

#### Immunosuppressants (IS), n (%)

| IS                | 1 | 2    | 3       | p-value |
|-------------------|---|------|---------|---------|
| CS                | 14 (82) | 4 (27) | 3 (20) | <0.001  |
| CNI               | 9 (53)  | 4 (27) | 9 (60)  | 0.74    |
| AZA               | 2 (12)  | 0 (0)  | 1 (7)   | 0.53    |
| MMF               | 6 (33)  | 2 (13) | 5 (33)  | 0.86    |
| MTOR              | 1 (6)   | 0 (0)  | 1 (7)   | 0.24    |
| Other IS          | 0 (0)   | 0 (0)  | 1 (7)   | 0.21    |

#### Laboratory Data

**Pre-Treatment**

| Parameter                  | 1          | 2          | 3          | p-value |
|----------------------------|------------|------------|------------|---------|
| WBC (cells/L x10⁹)         | 6.2        | 6.4        | 4.9        | 0.71    |
| Neutrophil %, median       | 60         | 54         | 57         | 0.48    |
| Lymphocyte %, median       | 25         | 30         | 26         | 1.00    |
| Eosinophil %, median       | 1.5        | 1.8        | 3.7        | 0.02    |
| Platelet count (K/cumm)    | 172        | 204        | 148        | 0.22    |
| Na (mg/dl), median         | 137        | 137        | 138        | 0.50    |
| Cr (mg/dl), median         | 0.81       | 0.67       | 0.87       | 0.83    |
| ALP (U/L), median          | 199        | 122        | 213        | 0.39    |
| AST (U/L), median          | 98         | 353        | 107        | 0.66    |
| ALT (U/L), median          | 120        | 297        | 111        | 0.64    |
| TB (mg/dl), median         | 1.3        | 4.5        | 1.2        | 0.70    |
| Albumin (g/dl), median     | 3.6        | 3.8        | 3.3        | 0.35    |
| Total protein (mg/dl), median | 6.8          | 7.4        | 7.0        | 0.41    |
| IgG, Total (mg/dl), median | 1.617      | 2.496      | 2.420      | 0.14    |
| ANA titer (≥1:80), n (%)   | 9 (60)     | 11 (79)    | 7 (54)     | 0.78ᵇ   |
| ASMA (≥20 U), n (%)        | 10 (71)    | 8 (67)     | 4 (36)     | 0.09ᵇ   |

**On Treatment**

**Day 7–10 (% change from pre-treatment, median)**

| Parameter | 1          | 2          | 3          | p-value |
|-----------|------------|------------|------------|---------|
| ALP       | -19.4      | -15.5      | -15.1      | 0.92    |
| AST       | -40.0      | -71.1      | -65.9      | 0.16    |
| ALT       | -42.8      | -44.9      | -60.7      | 0.19    |
| TB        | -13.8      | -28.6      | -27.8      | 0.46    |

**Day 30–60 (% change from pre-treatment, median)**

| Parameter | 1          | 2          | 3          | p-value |
|-----------|------------|------------|------------|---------|
| ALP       | -23.9      | -29.3      | -25.0      | 0.74    |
| AST       | -42.4      | -78.5      | -78.9      | 0.08    |
| ALT       | -43.4      | -69.9      | -74.6      | 0.13    |
| TB        | -15.9      | -68.5      | -28.2      | 0.54    |

#### Histopathologic data

| Fibrosis, n (%) | Mild/minimal | 7 (41) | 7 (47) | 10 (67) | 0.57ᵇ |
|-----------------|--------------|--------|--------|---------|-------|
| Moderate/severe | 10 (59)      | 8 (53) | 5 (33) |
| Portal inflammation, n (%) | 5 (29) | 0 (0) | 4 (27) |
| Mild/minimal    | 12 (71)      | 15 (100) | 11 (73) |
| Moderate/severe | 14 (82)      | 7 (47) | 8 (53) |
| Lobular inflammation, n (%) | 3 (18) | 8 (53) | 7 (47) |
| Mild/minimal    | 17 (100)     | 5 (33) | 8 (53) |
| Moderate/severe | 0 (0)        | 10 (67) | 7 (47) |
| Interface hepatitis, n (%) | 8 (47) | 13 (87) | 11 (73) |
| Perivenular necrosis, n (%) | 3 (18) | 8 (53) | 3 (20) |
| Bridging necrosis, n (%) | 2 (12) | 7 (47) | 3 (20) |

IS, immunosuppressants; CS, corticosteroids; CNI, calcineurin inhibitor; AZA, azathioprine; MMF, mycophenolate mofetil; mTOR, mammalian target of rapamycin inhibitor; TB, total bilirubin; ANA, anti-nuclear antibody; ASMA, anti-smooth muscle antibody.

ᵃPercent with data available.
ᵇFisher’s exact test. Binary comparisons made using “mild/minimal” vs. other where relevant.
TABLE 5 | Comparison of treatment response of post-LT PCH stratified by diagnosis and IgG4-Positivity.

| Laboratory data | Diagnosis | IgG4-positivity |
|-----------------|-----------|----------------|
|                 | rAIH      | PCR            | p-value | <0.500 | ≥0.500 | p-value |
|                 | N = 8     | N = 14         |         |         |         |         |
| ALP             | −11.6     | −24.9          | 0.48    |         |         | 0.37    |
| AST             | −23.7     | −65.9          | 0.11    |         |         | 0.04    |
| ALT             | −20.2     | −61.0          | 0.34    |         |         | 0.11    |
| TB              | −0.1      | −25.8          | 0.36    |         |         | 0.16    |
|                 | N = 17    | N = 5          |         | <0.500  |         |         |
| ALP             | −2.9      | −34.5          | 0.10    | −23.9   | −27.8   | 0.57    |
| AST             | −31.5     | −72.7          | 0.12    | −54.5   | −91.1   | 0.27    |
| ALT             | −17.8     | −68.8          | 0.12    | −36.4   | −79.6   | 0.41    |
| TB              | −7.9      | −18.3          | 0.62    | −16.7   | +46.7   | 0.36    |

*Percent change = (Value at Index Biopsy − Value at Day X)/Value at Index Biopsy. Bolded values represent statistically significant difference (p < 0.05).

Association Between IgG4-Positivity and Clinical Presentation

To better understand the clinical implication of IgG4-PC infiltration in PCH, we evaluated the potential association between IgG4-Positivity, laboratory parameters, histopathology and therapeutic outcomes. Our analysis showed that increasing tertile of IgG4-Positivity was associated with increasing peripheral eosinophil percentage (p = 0.02). This is consistent with the findings seen in other IgG4-RD (32). The proportion of subjects with CS use at the time of the biopsy decreased with increasing tertile of IgG4-Positivity (p < 0.001). Alternatively, no statistically significant trends were detected between degree of IgG4-Positivity and serum white blood cell count (p = 0.71), serum sodium (p = 0.50), serum creatinine (p = 0.83), ALP (p = 0.39), AST (p = 0.66), ALT (p = 0.64), or total bilirubin (p = 0.70) at time of biopsy (Table 4). Notably, no significant association was detected between IgG4-Positivity and serum IgG level (p = 0.14) or elevated ANA titer (≥1:40) (p = 0.78). ASMA positivity decreased by tertile of IgG4-Positivity from 71% to 36% in the lowest to highest tertiles, although this trend did not achieve statistical significance (p = 0.09). The relationship between serum IgG4 level and IgG4-Positivity could not be assessed due to limited data, though prior studies have shown that serum IgG4 concentration does not serve as the surrogate for the degree of IgG4-PC infiltration in the liver (28).

Histologically, higher degree of IgG4-Positivity was associated with severe necro-inflammatory change in the histological assessment (Table 4). The proportion of subjects with moderate or severe perivenular inflammation (p = 0.04) and lobular information (p = 0.005) increased with tertile of IgG4-Positivity but was not significantly associated with presence of moderate or severe fibrosis (p = 0.57).

To understand the association between IgG4-Positivity and biochemical response to treatment in the post-LT setting, an analysis comparing responsiveness (percent improvement from index biopsy) of liver-related serologic tests (ALP, AST, ALT, TB) of current diagnoses (rAIH and PCR) to IgG4-Positivity strata (<0.500 and ≥0.500) was performed. High IgG4-Positivity (≥0.500), all of which were PCR cases, was associated with greater improvement of AST (p = 0.04) at 7–10 days after treatment initiation. However, no significant difference was found when comparing by diagnosis (p = 0.11) (Table 5). The % improvement in AST at later time point (30–60 days) also increased with increasing tertile of IgG4-Positivity, though did not reach statistical significance (p = 0.08) (Table 4).

In summary, our analysis suggests that the high degree of IgG4-PC proliferation is associated with the histological features of severe inflammation in non- and post-LT setting, as well as more rapid response to IS in the post-LT setting.

DISCUSSION

This represents the first study to comprehensively evaluate the degree of IgG4-PC infiltration across types of PCH in the non- and post-transplant setting. Notably, our results showed a high degree of IgG4-PC infiltration more frequently associated with the clinical diagnosis of PCR than tnAIH, fAIH, and rAIH. In particular, markedly high IgG4-Positivity (≥0.500) was only found in PCR cases. This implies that IgG4-PC infiltration to this extent is not a general immune response to a liver allograft, rather appears to be a unique immunopathological fingerprint of PCR (Figure 2). We also note that there are cases of PCR with minimal or absent of IgG4-PC infiltration. Accordingly, the overlapping profiles of rAIH and some cases of PCR (IgG4-Positivity <0.500) raises the possibility a shared immunopathology in these two separate clinical entities (Figure 2). These findings may support prior hypotheses that a pathophysiologically-distinct de novo AIH exists separately from PCR (33). Moreover, there are some cases with relatively high degree of IgG4-PC infiltration (IgG4-positivity >0.20) in AIH cases, especially in tnAIH group. These observations collectively indicate that each PCH disease consists of heterogeneous immunophenotypes. Additionally, we found that differentiation of PCH by IgG4-positivity may be of direct clinical relevance in the post-LT setting. The group with markedly high IgG4-Positivity (≥0.500) appears to demonstrate a more rapid response to directed IS. Consequently, our study suggests that evaluation of IgG4-Positivity may serve as a valuable diagnostic approach in the post-LT setting with corresponding implications in management. Additionally, the lack of rAIH cases with markedly high IgG4-Positivity in our study suggests that IgG4-Positivity may be of diagnostic utility when pre-LT diagnoses is unclear or unknown. Specifically, an IgG4-Positivity threshold of ≥0.500 may effectively rule out a diagnosis of rAIH. This is of potential therapeutic relevance as rAIH has been known to require aggressive immunosuppression to prevent graft loss (14).

To date, there remain substantial gaps in understanding the underlying pathophysiology of PCH, which significantly hinders clinical management of PCH diseases. In particular, there is concern as to whether each PCH disease represents a distinctive condition or a cluster of broader, overlapping conditions than current classification schemes. The latter case might, at least in part, be the basis for the variable degree of response to IS among and within the PCH diseases. Current management strategies of PCH entirely
IgG4 is known to have a unique immunomodulatory effect distinct from other types Ig (24). Other than antigen binding, Ig plays an important role in activation of the immune system through two discrete mechanisms: 1) Ig binding to fragment crystallizable (Fc) receptors (FcR) expressed on the cell surface of various immune cells, which augment the cytotoxic and phagocytic function of immune cells, and 2) Ig interaction with complement component 1q (C1q), resulting in activation of classical complement pathway. Of great interest, IgG4 has been considered a non-inflammatory IgG compared with other IgG subclasses due to stronger affinity to the inhibitory FcR, Fcy receptor IIB, and an inferior capacity in complement pathway activation (41, 42). These notions regarding the “non-inflammatory” characteristics of IgG4 appears irrelevant in PCH, at least in our study, as our observations revealed that IgG4-Positivity is associated with higher degree of hepatic necroinflammation. A potential explanation is that IgG4-PCs may serve an anti-inflammatory role when severe inflammation is present. Interestingly, despite the positive association of IgG4-Posivity with inflammation severity, there was no difference with respect to liver biochemistries at biopsy (Table 4).

It has been shown that the production of IgG4 involves an activation of unique upstream immune pathway, in which interleukin (IL)-4 and IL-10 secreted from CD4+ (C-X-C chemokine receptor type-5) CXCR5+ T cell, namely Tfh cells, facilitates transdifferentiation of naive B cells to IgG4-PC (43–45). Accordingly, affected organs in IgG4-RD exhibit an abundant infiltration of Tfh cells (45, 46). In addition, the clonal expansion of CD4+ T cells with a cytotoxic function (CD4+ CTLs), which abundantly express SLAM family member 7 (SLAMF7), granzyme A (GZMA), IL-1β, and TGF-β, is observed in the affected organ of IgG4-RD (47, 48). TGF-β is a potent anti-inflammatory cytokine and contributes to the fibrosis development. Thus, development of fibrosis a hallmark feature of IgG4-RD. However, we observed that infiltration of IgG4-PC was not associated with fibrosis severity. This potential discrepancy between IgG4-RD and PCH with IgG4 PC infiltration may be partially due to the close laboratory monitoring of AIH and post-LT patients, resulting in up-titration of IS before the development of infection and malignancy. While the current empiric management strategy is capable of inducing remission in a large proportion of patients, the prognosis of individuals with PCH remains highly variable. In the non-LT setting, transplant-free survival of AIH is 91% and 70% at 10 and 20 years from the initial diagnosis, respectively, with up to 40% progressing to cirrhosis despite treatment (18, 34). Similarly, rAIH is responsible for 1% of all deaths at 5 years post-transplantation due to graft failure and is associated with increased risk of death from infection (14). With regards to PCR, the overall prognosis in adults is not well defined, although studies in pediatric populations demonstrate no significant impact on the prognosis (35, 36). Though PCR typically responds well to increased doses of corticosteroids, it is understood that non- or under-treated patients eventually progress to graft loss (13). As use of IS also carries its own risks (19, 37), an establishment of a specific, molecular-targeted therapeutic strategy that abrogates off-target toxicities provides an opportunity to improve patient outcomes.

Given advancement in understanding of IgG4-RD, there has been increasing interest in the involvement of IgG4-PC in liver diseases. The pioneer work examined the liver tissue of autoimmune pancreatitis patients with liver enzyme abnormalities, in which the dense infiltration of IgG4-PC in the liver parenchyma was observed in nearly all cases (28). Since the histopathological findings also exhibited multiple features commonly seen in AIH, further studies investigating the presence of IgG4-PC in the liver tissue of patients with AIH were performed (38–40). These studies found an infiltration of IgG4-PC in a small proportion of cases based on the criteria of >5 or 10 IgG4-PC per high power field (HPF). In contrast, more pronounced degree of IgG4-PC infiltration, >25 IgG4-PC per HPF was noted in cases of PCR (29). While these findings led to substantial excitement into the field, the definition of the “IgG4-PC infiltration” determined in a binary fashion (e.g. “positive” or “negative”) or the number of cells staining positive for IgG4 per HPF might not serve as an objective indicator since it lacks the consideration of the total number of PC aggregated in the corresponding foci. To date, the lack of a standardized evaluation method for IgG4-PC infiltration has severely limited its clinical utility—despite expert acknowledgement of its importance in prior consensus statements (12). To overcome this fundamental issue, we established a rigorous approach to better evaluate the degree of IgG4-PC infiltration. To this end, we determined the frequency of IgG4-PC by normalizing the number of IgG4-PC over the total number of PCs in the corresponding portal tracts using serially sectioned slides (IgG4-Positivity). In addition, we sought to minimize the risk of data interpretation bias resulting from the potential sampling error by enrolling only samples that have at least 8 portal tracts, of which the foci with the representative tracts were used to evaluate the degree of IgG4-PC infiltration. We believe our quantification system allows objective cross-sectional evaluation of IgG4-PC infiltration.
group (Table 5). Moreover, the strong association of decreasing IgG4-Positivity and CS use is also congruent with existing paradigm of steroid-responsiveness in IgG4-RD (Table 4). These observations suggest that evaluating IgG4-Positivity has a direct relevance to clinical management of PCH, particularly in the post-LT setting, as it may be of prognostic value in assessing expected response to corticosteroid therapy.

In summary, this study is the first to cross-sectionally demonstrate the diversity of the immunophenotypic profile of PCH in the non- and post-transplant setting, in the absence and presence of IS, as defined by IgG4-Positivity—with significant differences across and within disease entities. The highly heterogenous IgG4-Positivity across and within PCH entities indicate that current classification of PCH diseases is insufficient in capturing the immuno-pathophysiology. Hence, we propose refining the PCH classification strategy by incorporating the IgG4-Positivity based stratified categorization, particularly in the post-LT setting; which might inform a immunopathology-specific management strategy and prognostication. Toward this goal, further prospective studies with a larger number of subjects treated with a standardized IS regimen, and long-term follow up, are warranted.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

REFERENCES

1. Demetris AJ, Sebagh M. Plasma Cell Hepatitis in Liver Allografts: Variant of Rejection or Autoimmune Hepatitis? Liver Transpl (2008) 14(4):750–5. doi:10.1002/lt.21518
2. Guindi M. Histology of Autoimmune Hepatitis and its Variants. Clin Liver Dis (2010) 14(4):577–90. doi:10.1016/j.cld.2010.07.003
3. Czaja AJ, Carpenter HA. Histological Findings in Chronic Hepatitis C with Autoimmune Features. Hepatology (1997) 26(2):459–66. doi:10.1002/hep.510260229
4. Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, et al. Autoimmune Hepatitis. Nat Rev Dis Primers (2018) 4:18017. doi:10.1038/nrdp.2018.17
5. Page AR, Good RA. Plasma-cell Hepatitis, with Special Attention to Steroid Therapy. Arch Pediatr Adolesc Med (1966) 99:288–314. doi:10.1001/archpedi.1966.02700302990006
6. Perez-Soler R, Esteban R, Allende J, Saloma CT, Julia A, Guardia J. Liver Involvement in Multiple Myeloma. Am J Hematol (1985) 20(1):25–9. doi:10.1002/ajh.2830201005
7. Fiel MI, Agarwal K, Stanca C, Elhaij N, Kontorinis N, Thung SN, et al. Posttransplant Plasma Cell Hepatitis (De Novo Autoimmune Hepatitis) Is a Variant of Rejection and May Lead to a Negative Outcome in Patients with Hepatitis C Virus. Liver Transpl (2008) 14(6):861–71. doi:10.1002/lt.21447
8. Kerkar N, Yanni G. ‘De Novo’ and ‘recurrent’ Autoimmune Hepatitis after Liver Transplantation: A Comprehensive Review. J Autoimmun (2016) 66:17–24. doi:10.1016/j.jaut.2015.08.017
9. Czaja AJ. Diagnosis, Pathogenesis, and Treatment of Autoimmune Hepatitis after Liver Transplantation. Dig Dis Sci (2012) 57(9):2248–66. doi:10.1007/s12197-012-2179-3
10. Mendes F, Couto CA, Levy C. Recurrent and De Novo Autoimmune Liver Diseases. Clin Liver Dis (2011) 15(4):859–78. doi:10.1016/j.cld.2011.08.008

AUTHOR CONTRIBUTIONS

BH participated in the conceptual design of the study; BH, TL, SC, JK, and TS participated in the performance of the research. BH and JD participated in the data analysis and manuscript preparation. JK and TS designed the study and oversaw manuscript preparation.

FUNDING

Departmental Research Fund (TS) and USC Research Center for Liver Diseases (P30DK048522) (JD).

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

ACKNOWLEDGMENTS

The authors would like to thank Dr. Ryuta Kamekura at the Sapporo Medical University School of Medicine for his critical input and discussion.

11. Fiel MI, Schiano TD. Plasma Cell Hepatitis (De-novo Autoimmune Hepatitis) Developing post Liver Transplantation. Curr Opin Organ Transpl (2012) 17(3):287–92. doi:10.1097/mot.0b013e3283566262
12. Demetris AJ, Bellamy C, Hubscher SG, O’Leary J, Randhawa PS, Feng S, et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transpl (2016/02/10) 16(10):2816–35. doi:10.1111/ajt.13990
13. Salcedo M, Vaquerio J, Bañares R, Rodríguez-Mahou M, Alvarez E, Vicario JL, et al. Response to Steroids in De Novo Autoimmune Hepatitis after Liver Transplantation. Hepatology (2002) 35(2):349–56. doi:10.1053/hep.2002.31167
14. Heinemann M, Adam R, Berenguer M, Mirza D, Malek-Hosseini SA, O’Grady JG, et al. Longterm Survival after Liver Transplantation for Autoimmune Hepatitis: Results from the European Liver Transplant Registry. Liver Transpl (2020) 26(7):866–77. doi:10.1002/lt.25739
15. Gleeson D. Long-Term Outcomes of Autoimmune Hepatitis. Clin Liver Dis (2019) 14(1):24–8. doi:10.1016/j.clod.2019.01.002
16. Kwon IH, Hanouneh IA, Allende D, Yerian L, Diago T, Eghtesad B, et al. De Novo Autoimmune Hepatitis Following Liver Transplantation. Transplant Proc (2018) 50(5):1451–6. doi:10.1016/j.transproceed.2018.02.066
17. Ward SC, Schiano TD, Thung SN, Fiel MI. Plasma Cell Hepatitis in Hepatitis C Virus Patients post-liver Transplantation: Case-Control Study Showing Poor Outcome and Predictive Features in the Liver Explant. Liver Transpl (2009) 15(12):1826–33. doi:10.1002/lt.21949
18. Verma S, Gunawan B, Mendler M, Govindrajan S, Redeker A. Factors Predicting Relapse and Poor Outcome in Type I Autoimmune Hepatitis: Role of Cirrhosis Development, Patterns of Transaminases during Remission and Plasma Cell Activity in the Liver Biopsy. Am J Gastroenterol (2004) 99(8):1510–6. doi:10.1111/j.1572-0241.2004.30457.x
19. Charlton M, Levitsky J, Aqel B, O’Grady J, Hembich J, Rinella M, et al. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation (2018) 102(5):727–43. doi:10.1097/tp.000000000002147

Transplant International | Published by Frontiers

March 2022 | Volume 35 | Article 10182
20. Nakazawa Y, Walker NI, Kerlin P, Steadman C, Lynch SV, Strong RW, et al. Clinicopathological Analysis of Liver Allograft Biopsies with Late Centrilobular Necrosis. Transplantation (2000) 69(8):1599–608. doi:10.1097/00007890-200004270-00014

21. Zhang Y, Wang B, Wang T. De Novo autoimmune Hepatitis with Centrilobular Necrosis Following Liver Transplantation for Primary Biliary Cirrhosis: a Case Report. Transplant Proc (2010) 42(9):3854–7. doi:10.1016/j.transproceed.2010.08.062

22. Zhao X-y., Rakhda MIA, Wang T-I, Jia J-d.. Immunoglobulin G4-Associated Autoimmune Hepatitis with Centrilobular Necrosis: a Case Report. J Hepatol (2019) 71(5):664–8. doi:10.1016/j.jhep.2019.02.049

23. Gupta P, Hart J, Mills JM, Cronin D, Brady L. De Novo Hepatitis with Autoimmune Antibodies and Atypical Histology. Transplantation (2001) 71(5):664–8. doi:10.1097/00007890-200103150-00016

24. Vidarsson G, Dekkers G, Rispens T. IgG Subclasses and Allotypes: from Structure to Efferctor Functions. Front Immunol (2014) 5:250. doi:10.3389/ fi.immuno.2014.00520

25. Nurieva RI, Chung Y. Understanding the Development and Function of T Follicular Helper Cells. Cell Mol Immunol (2010) 7(3):190–7. doi:10.1038/cmi.2010.24

26. Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-Associated Cholangitis: Clinical Profile and Response to Therapy. Gastroenterology (2008) 134(3):706–15. doi:10.1053/j.gastro.2007.12.009

27. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus Statement on the Pathology of IgG4-Related Disease. Mod Pathol (2012) 25(9):1181–92. doi:10.1038/modpathol.2012.72

28. Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K. Immunoglobulin G4-Hepatopathy: Association of Immunoglobulin G4-Bearing Plasma Cells in Liver with Autoimmune Pancreatitis. Hepatology (2007) 46(2):463–71. doi:10.1002/hep.21700

29. Castillo-Rama M, Sebagh M, Sasatomi E, Randhawa P, Isse K, Salgarkar AD, et al. ‘ Plasma Cell Hepatitis’ in Liver Allografts: Identification and Characterization of an IgG4-Rich Cohort. Am J Transpl (2013) 13(11):2966–77. doi:10.1111/ajt.12413

30. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines from the American Association for the Study of the Liver Diseases. Hepatology (2020) 72(2):671–722. doi:10.1002/hep.31065

31. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mielni-Vergani G, Vergani D, et al. Diagnosis and Management of Autoimmune Hepatitis. Hepatology (2010) 51(6):2193–213. doi:10.1002/hep.23584

32. Mohapatra S, Charlauou P, Sharma A, Singh DP, Sah RP, Murray D, et al. Significance of Peripheral Eosinophilia for Diagnosis of IgG4-Related Disease in Subjects with Elevated Serum IgG4 Levels. Pancreatology (2020) 20(1):74–8. doi:10.1016/j.pan.2019.01.016

33. Strinnamin G, Ehab M, Czaja AJ, Montano-Loa ZAJ. Recurrent and De Novo Autoimmune Hepatitis. Liver Transpl (2019) 25(1):152–66. doi:10.1002/lt.25375

34. Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, et al. Long-term Outcomes of Patients with Autoimmune Hepatitis Managed at a Nontransplant center. Gastroenterology (2011) 140(7):1980–9. doi:10.1053/j.gastro.2011.02.065

35. Beal EW, Black SM, Michaels A. Autoimmune Hepatitis in the Liver Transplant Graft. Clin Liver Dis (2017) 21(2):381–401. doi:10.1016/j.cld.2016.12.010

36. Pongpaibul A, Venick RS, McDarmid SV, Lassman CR. Histopathology of De Novo Autoimmune Hepatitis. Liver Transpl (2012) 18(7):811–8. doi:10.1002/ lt.23422

37. Wiesner R, Rabkin J, Klintmalm G, McDarmid S, Langnas A, Punch J, et al. A Randomized Double-Blind Comparative Study of Mycophenolate Mofetil and Azathioprine in Combination with Cyclosporine and Corticosteroids in Primary Liver Transplant Recipients. Liver Transplant (2001) 7(5):442–50. doi:10.1053/jlts.2001.23356

38. Aydemir Y, Akcoren Z, Demir H, Saltik Temizel IN, Ozen H, Yuce A. Clinical and Histopathological Features of Immunoglobulin G4-associated Autoimmune Hepatitis in Children. J Gastroenterol Hepatol (2019) 34(4):742–6. doi:10.1111/jgh.14525

39. Amarapurkar AD, Amarapurkar DN. Immunoglobulin IgG4 and autoimmune hepatitis. Trop Gastroenterol (2015) 36(2):112–7. doi:10.7869/tg.263

40. Chung H, Watanabe T, Kudo M, Maenishi O, Wakatsuki Y, Chiba T. Identification and Characterization of IgG4-Associated Autoimmune Hepatitis. Liver Int (2010) 30(2):222–31. doi:10.1111/j.1478-3231.2009.02092.x

41. Bindon CI, Hale G, Brüggemann M, Waldmann H. Monoclonal IgG Isotypes Differ in Complement Activating Function at the Level of C4 as Well as C1q. J Exp Med (1988) 168(1):127–42. doi:10.1084/jem.168.1.127

42. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and Affinity of Human Fc Receptors and Their Polymorphic Variants for Human IgG Subclasses. Blood (2009) 113(16):3716–25. doi:10.1182/blood-2008-09-179754

43. Kamekura R, Takahashi H, Ichimiya S. New Insights into IgG4-Related Disease: Emerging New CD4+ T-Cell Subsets. Curr Opin Rheumatol (2019) 31(1):9–15. doi:10.1097/bor.0000000000000558

44. Maehara T, Moriyma M, Nakamura S. Pathogenesis of IgG4-Related Disease: a Critical Review. Odontology (2019) 107(2):127–32. doi:10.1002/smd.0018:0377-y

45. Kamekura R, Takano K, Yamamoto M, Kawata K, Shigehara K, Jitsukawa S, et al. Cutting Edge: A Critical Role of Lesional T Follicular Helper Cells in the Pathogenesis of IgG4-Related Disease. J.I. (2017) 199(8):2624–9. doi:10.4049/ jimmunol.1601507

46. Chen Y, Lin W, Yang H, Wang M, Zhang P, Feng R, et al. Aberrant Expansion and Function of Follicular Helper T Cell Subsets in IgG4-Related Disease. Arthritis Rheumatol (2018) 70(11):1853–65. doi:10.1002/art.40556

47. Mattow H, Mahajan VS, Maehara T, Deshpande V, Della-Torre E, Wallace ZS, et al. Clonal Expansion of CD4+ Cytotoxic T Lymphocytes in Patients with IgG4-Related Disease. J. Allergy Clin Immunol (2016) 138(3):825–38. doi:10.1016/j.jaci.2015.12.1330

48. Barranco C. CD4+ CTLs Drive IgG4-Related Disease. Nat Rev Rheumatol (2016) 12(9):500. doi:10.1038/nrrheum.2016.124

49. Heneghan M, Portmann BC, Norris SM, Williams R, Muijesan P, Rela M, et al. Graft Dysfunction Mimicking Autoimmune Hepatitis Following Liver Transplantation in Adults. Hepatology (2001) 34(3):464–70. doi:10.1053/jhep.2001.26756

50. Liberal R, Longhi MS, Grant CR, Mieli–Vergani G, Vergani D. Autoimmune Hepatitis after Liver Transplantation. Clin Gastroenterol Hepatol (2012) 10(4):346–53. doi:10.1016/j.cgh.2011.10.028
GLOSSARY

AIH autoimmune hepatitis
ANA anti-nuclear antibody
ASMA anti-smooth muscle antibody
AZA azathioprine
BMI body mass index
CD4+ cluster of differentiation 4 positive
CD4+ CTLs CD4+ T cells with a cytotoxic function
CNI calcineurin inhibitor
CS corticosteroids
CTL cytotoxic T lymphocyte
CXCR5 C-X-C chemokine receptor type 5
fAIH flare of autoimmune hepatitis
Fc fragment crystallizable
FcR Fc receptor
FFPE formalin-fixed paraffin embedded
GZMA granzyme A
H&E hematoxylin-eosin

Ig immunoglobulin
IgG4 immunoglobulin G subclass 4
IgG4-PC IgG4-producing plasma cells
IgG4-RD IgG4-related disease
IHC immunohistochemical
IL interleukin
IS immunosuppressants
LT liver transplantation
MMF mycophenolate mofetil
mTOR mammalian target of rapamycin
PC plasma cell
PCH plasma cell hepatitis
PCR plasma cell-rich rejection
rAIH recurrent autoimmune hepatitis
SLAMF7 SLAM family member 7
Tfh T follicular helper
TGF-β transcription growth factor-β
tnAIH treatment-naïve autoimmune hepatitis